Mira pharmaceuticals inc MIRA.US 總覽分析
MIRA 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
公司發布財報數據季度不足，尚無法提供評分
MIRA 近期報酬表現
1.75%
Mira pharmaceuticals inc
3.56%
同產業平均
1.47%
S&P500
與 MIRA 同產業的標的表現
- PVLA Palvella therapeutics inc價值 2 分趨勢 3 分波段 5 分籌碼 2 分股利 1 分查看更多
MIRA 公司資訊
MIRA Pharmaceuticals, Inc. is a clinical-stage pharmaceutical development company. The Company has two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. It holds exclusive license rights in the United States, Canada and Mexico for Ketamir-2 and MIRA-55, two novel drug candidates designed to address unmet medical needs in pain management, depression, PTSD and cognitive function. Ketamir-2 is a patent-pending oral ketamine analog evaluated for the treatment of diabetic neuropathy and is in an ongoing Phase I clinical trial. It is for patients suffering from neuropathic pain, treatment-resistant depression (TRD), major depressive disorder with suicidal ideation (MDD-SI), and post-traumatic stress disorder (PTSD). MIRA-55 is a preclinical-stage investigational drug designed to support cognitive function and enhance memory. It is for the treatment of patients experiencing cognitive decline, including those with early neurodegenerative conditions.